Case Report: Disease progression of renal cell carcinoma containing a novel putative pathogenic fusion on Ipilimumab- Nivolumab immunotherapy. A case study and review of the literature.

Renal cell carcinoma still carries a poor prognosis despite therapeutic advancements. Detection of genetic mutations is vital in improving our understanding of this disease as well as potential role in targeted therapy. Here we present a case of a 49 year old man with an aggressive renal cell carcinoma bearing a novel pathogenic fusion.